With a 170-year heritage, Aspen is a global specialty and branded multinational pharmaceutical company with a presence in both emerging and developed markets. We have more than 9 100 employees at 65 established offices in over 50 countries and we improve the health of patients in more than 115 countries through our high quality, affordable medicines.
Aspen focuses on marketing and manufacturing a broad range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets through our key business segments. Our key business segments are Manufacturing and Commercial Pharmaceuticals comprising Regional Brands and Sterile Focus Brands. Our manufacturing capabilities cover a wide variety of product types including steriles, oral solid dose, liquids, semi-solids, biologicals and active pharmaceutical ingredients.
We operate 23 manufacturing facilities across 15 sites and we hold international manufacturing approvals from some of the most stringent global regulatory agencies including, among others, the United States Food and Drug Administration, the Australian Therapeutic Goods Administration and the European Directorate for the Quality of Medicines.
Classification:
Qualification:
Appointment:
Group Chief Executive
CA(SA), PhD (Commerce) Honoris Causa
January 1999
Stephen is a founding shareholder of the Aspen Group and his responsibilities include strategic positioning and global transactions, geographic expansion and product diversification of Aspen in developed and emerging markets as a leading multinational pharmaceutical company.
Classification:
Qualification:
Appointment:
Group Chief Financial Officer
CA(SA)
January 2022
Sean is responsible for all of the Group’s finance functions across Aspen’s 60 businesses. He also assesses business performance and identifies business improvement opportunities.
Classification:
Qualification:
Appointment:
Independent Non-executive, Chairman
MPhil (Oxon), BSocSci (Hons) (Natal), Global Leadership for the 21st Century Programme (Harvard), Foundations for Leadership in the 21st Century (Yale)
April 2012
Kuseni is the Chairman of Massmart Holdings Limited. He was previously Chairman of Times Media Group Limited and Chief Executive Officer of Old Mutual South Africa and Emerging Markets. He brings a wealth of economic and business skills to the Board, having previously held positions as the head of Anglo American South Africa and Executive Chairman of Richards Bay Coal Terminal Company.
Kuseni is the former Chairman of the South African National Parks and a former member of the Global Agenda Council on Economic Growth and Poverty Alleviation formed by the World Economic Forum. He is active in academic and professional bodies, which include the Council of the University of Pretoria, the South African Institute of International Affairs, and the advisory boards of the Gordon Institute of Business Science and Common Purpose.
Kuseni is a member of the Remuneration & Nomination Committee and the Social & Ethics Committee.
Classification:
Qualification:
Appointment:
Independent Non-executive
CA(SA), MCom (Tax), CD(SA)
July 2018
Linda serves as an independent non-executive director on a number of JSE listed boards, namely Momentum Metropolitan Holdings Limited, Tongaat Hulett Limited and Shoprite Holdings Limited. She chairs or serves on the audit committees of these boards and also serves on a number of their other board committees. She was previously a member of numerous South African and international standard setting, oversight and corporate governance structures. In addition, chairs the board of trustees of the International Public Interest Oversight Board (PIOB), a non-profit foundation in Spain, and serves as a trustee of the International Valuations Standards Council (based in London).
Linda serves as the Chair of the Remuneration & Nomination Committee and is a member of the Audit & Risk Committee.
Classification:
Qualification:
Appointment:
Lead Independent Non-executive
BCom (Hons), CA(SA), Advanced Programme in Management (Harvard Business School)
April 2019
Ben joined Standard Merchant Bank in 1985 and, after having fulfilled various leadership roles in corporate and investment banking, was appointed as Chief Executive of Standard Bank Corporate and Investment Banking in 2001. In March 2013, Ben was appointed as Co-Chief Executive Officer of the Standard Bank Group Limited, and he retired from The Standard Bank Group on 31 December 2018. He currently serves as a non-executive director on the board of Stanbic IBTC Holdings Plc and Stanbic IBTC Bank Plc and as a non-executive director on the board of the JSE Limited. He is a member of the Institute of Directors of Southern Africa and served on the board of the International Institute of Finance. Ben is also a member, and serves as Deputy Chair, of the Council of the University of Pretoria.
Ben serves as the Chair of the Audit & Risk Committee, and is a member of the Social & Ethics Committee.
Classification:
Qualification:
Appointment:
Independent Non-executive
B.Eng (Hons)
April 2019
Classification:
Qualification:
Appointment:
Non-executive
BA, LLB
January 1999
Chris has been a full-time practising attorney since 1988 and has substantial legal and commercial expertise. His intimate knowledge of the Group, its business operations and governance processes have been of immense benefit to Aspen over the years and he continues to serve the Board as a trusted adviser. As Chris’s firm is intermittently called upon to provide legal advice to the Group, he is classified as a non-independent non-executive director.
Classification:
Qualification:
Appointment:
Independent Non-executive
D.Phil (Oxford), MA (Political Science), BA (Hons)
December 2021
Yvonne currently serves as Chairperson of the Rhodes Food Group, and as an independent non-executive director on the boards of the SA Reserve Bank and the SA SME Fund. She was also on the board of Thebe Investment Corporation, Chairperson of Bankserv and Chairperson of the Sasol Foundation. Yvonne previously served as Chief Executive: Group Services at Sanlam and Executive Director of Sanlam Ltd as well as Non-Executive Director of Santam, Sanlam Investments and Sanlam Investment Management. Preceding that she was Vice President of Public Affairs & Communications for Coca-Cola Africa based in London and Group Executive Corporate Affairs for the MTN Group Ltd. She also formerly served as a non-executive director for Aurecon, Sentech, MTN Nigeria, the SABC, and Transnet. She was the founding Executive Director of Democracy & Governance at the HSRC and Public Service Commissioner in President Mandela’s government.
Yvonne completed her D.Phil. degree in Sociology and Politics at Oxford University (UK) and holds a MA from Northwestern University (USA) as well as a BA and a BA (Hons) cum laude from the University of the Western Cape in South Africa. She previously held the position of Associate Professor in Sociology at the University of Natal, Durban.
She is widely published and has written and edited several books, articles and international conference papers. She completed ‘Leadership in Financial Organizations’ at Harvard Business School. She has also completed executive management courses at the Wits Business School, and the ‘Senior Executive Leadership’ programs of Coca-Cola in Atlanta, as well as MTN.
Yvonne serves as the Chair of the Social & Ethics Committee and is a member of the Audit & Risk Committee.
Classification:
Qualification:
Appointment:
Non-executive
BSc (Hons), CA
February 2015
David was appointed Chief Strategy Officer of GlaxoSmithKline Plc (“GSK”) in May 2008 and is responsible for corporate development and strategic planning. He has, in this role, assisted GSK in numerous bolt-on acquisitions, disposals and joint ventures, including the creation of the world-leading Consumer Healthcare company through the combination of GSK, consumer healthcare business firstly with Novartis’s business and subsequently in 2019 with Pfizer’s business. He is a member of GSK’s Corporate Executive Team and reports to the CEO. Prior to holding this position, he was responsible for the leadership of GSK’s business in Northern Europe from 2005 to 2008 and Central and Eastern Europe from 2002 to 2005. He joined Glaxo in 1994 in finance and progressed through a series of finance roles before becoming Finance Director of the European business in 1999.
In addition to his current role, David is Chairman of ViiV Healthcare Limited. ViiV is a joint venture between GSK, Pfizer and Shionogi and focuses specifically on the research and development and global commercialisation of medicines to treat HIV.
Classification:
Qualification:
Appointment:
Group Chief Executive
CA(SA), PhD (Commerce) Honoris Causa
January 1999
Stephen is a founding shareholder of the Aspen Group and his responsibilities include strategic positioning and global transactions, geographic expansion and product diversification of Aspen in developed and emerging markets as a leading multinational pharmaceutical company.
Classification:
Qualification:
Appointment:
Group Chief Financial Officer
CA(SA)
January 1999
Sean is responsible for all of the Group’s finance functions across Aspen’s 60 businesses. He also assesses business performance and identifies business improvement opportunities.
Classification:
Qualification:
Appointment:
Group Chief Advisor
CA(SA)
January 1999
Gus is a founding shareholder of Aspen and is responsible for the strategic and financial well-being of the Group while also identifying and pursuing appropriate corporate opportunities and global transactions that will further benefit Aspen and our stakeholders.
Classification:
Qualification:
Appointment:
Group Chief Corporate Services Officer
MBA, PGDBA, Graduate Diploma in Company Direction
May 2020
Reginald is responsible for managing Aspen’s cluster of Group Corporate Services functions. He also ensures the provision of efficient and effective services to the Group in accordance with business and legislative requirements. Reginald was appointed as a member of the Social & Ethics Committee on 1 September 2020.
Classification:
Qualification:
Appointment:
Group Chief Operations Officer and Responsible Pharmacist
BPharm
January 1999
Lorraine is responsible for multiple operational areas of the business, including strategic manufacturing, pharmaceutical affairs, new product development and strategic procurement. In addition, she plays an integral role in negotiation and implementation of new business initiatives for the Manufacturing business, which she also represents in global transactions.
Classification:
Qualification:
Appointment:
Chief Executive Officer, Aspen Global Incorporated
CMA, CFM, CBM, MBA
May 2008
Samer joined the Group with the responsibility of establishing the company to lead and direct its international operations. He has been integrally involved in the negotiation, completion and integration of strategic acquisitions, the setting up of the Group’s global businesses as well as the trading and supply structures to support these.
Classification:
Qualification:
Appointment:
Group Chief Strategic Development Officer
CA(SA), CFA, LLB
May 2020
Zizipho is responsible for focusing on assessing and implementing strategic development activities for the Group such as acquisitions, disposals and business development collaborations. She also plays an active role in advancing business performance and value enhancement opportunities.
Classification:
Qualification:
Appointment:
Senior Executive Strategic Trade
B.Pharm, FPS (SA), PhD (Medicine) Honoris Causa
January 1999
Stavros plays a pivotal role in the initiation of business development opportunities and is also key to the building and maintenance of strategic relations within industry and with all of Aspen’s stakeholders.
Classification:
Qualification:
Appointment:
Senior Group Executive: Commercial (International Regions)
Bachelor of Dental Science (BDS)
October 2022
Carnie is responsible for the development and implementation of strategy and the performance delivery of the Aspen Commercial Pharmaceutical business in Brazil, LATAM, USA, Canada, Europe, Russia-CIS, MENAT and SSA.
Classification:
Qualification:
Appointment:
Regional Chief Executive Officer, Asia Pacific
CA(SA)
May 2001
Trevor is responsible for the implementation of strategy and the performance delivery of Aspen’s Commercial Pharmaceutical businesses in Australasia, the Philippines, Taiwan, Malaysia and Hong Kong as well as trade into the rest of the Asia Pacific region. He plays a leading role in all transactional activity in the region.
Aspen Holdings
www.aspenpharma.com
Hotline (South Africa)
0800 122 912
Medical Careline (South Africa) 0800 118 088
ASPEN PHARMACARE HOLDINGS LTD:
Switchboard: +27 31 580-8600
Aspen Place
9 Rydall Vale Park
Douglas Saunders Drive
La Lucia Ridge
South Africa